Company intelligence / Profile preview

Curaxis Pharmaceutical

Raleigh, North Carolina, United States

Ownership: Private
Development stage: Other

Overview

Curaxis Pharmaceutical Corporation was a specialty pharmaceutical company focused on age-related diseases, particularly Alzheimer's disease and multiple cancers. It ceased operations in January 2016 following a Chapter 7 bankruptcy liquidation. The company completed Phase II clinical trials for leuprolide acetate in Alzheimer's disease patients and Phase I trials for VP4896 implants. Its assets have been liquidated.

Therapeutic areas: HematologyNeurologyOncology
Modalities: Small moleculeHormone
Industry: Biotech

Beyond the preview

Go deeper on Curaxis Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curaxis Pharmaceutical.

Explore the full profile